Alphavirus particles and methods for preparation
CA 2807515 C · Owner: Alphavax, Inc. · Inventors: Rayner, Jon; Alterson, Harold; Kamrud, Kurt
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided herein are methods for producing alphavirus replicon particles in high yield; replicon RNAs are electroporated into permissive cells where the cells are at a relatively high density together with at least one helper nucleic acid providing the necessary functions for packaging. After a growth period in appropriate medium alphavirus replicon particles are harvested from the surfaces of the cells in which they were produced using a salt wash in which the salt concentration is from about 0.2 to about 5 M sodium chloride calcium chloride, magnesium chloride, potassium chloride ammonium acetate, ammonium bicarbonate among others. After dilution, if necessary the particles can be purified …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 12, 2003 and granted February 4, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 12, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 12, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.